Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Paul Carlson

Status

Terminated

Conditions

Major Depressive Disorder

Study type

Observational

Funder types

Other

Identifiers

NCT01465165

WIBR08-PJC

Details and patient eligibility

About

Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders. The current study utilizes two distinct but complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and multinuclear magnetic resonance spectroscopy (MRS), to better understand the nature of these metabolic abnormalities in major depressive disorder (MDD). The investigators hypothesize that individuals with depression will have increased metabolic activity as measured by PET in certain brain regions involved in mood regulation, but that this metabolic activity will be inefficient based on MRS findings. For this study, the investigators will study 10 medication-free, currently depressed participants with recurrent MDD, 10 depressed participants with recurrent MDD currently taking antidepressant medication, and up to 20 healthy control participants matched to depressed participants for age and gender. Depressed and healthy participants will each undergo one PET scan and one MRS scanning session.

Enrollment

12 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Meet DSM-IV criteria for Major Depressive Disorder (MDD), Recurrent
Montgomery-Asberg Depression Rating Scale (MADRS) score > 18

Exclusion criteria

Any coexisting psychiatric illness other than generalized anxiety disorder, panic disorder, or social/specific phobias
Any history of substance dependence
Substance abuse within the past 6 months
Significant risk of suicide, as defined by score >4 on item 10 of the MADRS or in the clinical judgment of the study physician
Any significant medical or neurological condition which is likely to impact the central nervous system and/or affect the results of MRS or PET imaging
For the subset of unmedicated MDD patients, any psychotropic medications within 4 weeks prior to scanning. For the subgroup of medicated patients, they may be taking a stable dose (i.e., same dose for at least 4 weeks at the time of scanning) of standard antidepressant medications, but may not be taking any other psychotropic medication.
Inability to give informed consent
Contraindication to MRI (e.g., pacemaker, ferromagnetic implants in the body)